Viatris anticipates $500 million in net cost savings by 2028, with reinvestment supporting higher-value brands. Click to read ...
Dublin, April 16, 2024 (GLOBE NEWSWIRE) -- The "Selatogrel Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering. "Selatogrel Market Size, ...
Idorsia Ltd (SIX: IDIA) today announced the initiation of the Phase 3 registration study “SOS-AMI” to evaluate the efficacy and safety of self-administered subcutaneous selatogrel, Idorsia’s P2Y 12 ...
Idorsia Ltd (SIX: IDIA) today announced that it has reached an agreement with Viatris Inc. (NASDAQ: VTRS) to update the terms of the global development and commercialization collaboration for ...
ZURICH (Reuters) -Idorsia is launching a late-stage trial of its experimental heart-attack drug selatogrel that the Swiss company hopes will become what it describes as akin to an "EpiPen" for people ...
Allschwil, Switzerland - September 3, 2019 Idorsia Ltd (SIX: IDIA) today announced that the positive results of two Phase 2 clinical studies with selatogrel, a highly-selective P2Y 12 receptor ...
NEW YORK (Reuters Health) - A single subcutaneous dose of the investigation drug selatogrel, a reversible P2Y12-receptor antagonist, provides a rapid, dose-related antiplatelet response in patients ...
Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarctionAd hoc announcement pursuant to Art. 53 LRIdorsia to host an investor webcast to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results